{
    "nct_id": "NCT02886884",
    "official_title": "A Phase I/II, Randomized, Double Blind, Pilot Trial to Evaluate the Safety and Efficacy of Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects",
    "inclusion_criteria": "* Be ≥ 21 and < 90 (inclusive) years of age.\n* Provide written informed consent.\n* Have endothelial dysfunction defined by impaired flow-mediated vasodilation (FMD <7%).\n* Have an ejection fraction > 45% by gated blood pool scan, two- dimensional echocardiogram, cardiac MRI, cardiac CT or left ventriculogram within the prior 3 months.\n* Have Diabetes mellitus type 2 documented by hemoglobin adult type 1 component (A1C) > 7% or on medical therapy for diabetes.\n* Females of childbearing potential must use two forms of birth control for the duration of the study. Female subjects must undergo a blood or urine pregnancy test at screening and within 36 hours prior to infusion.\nHealthy volunteers allowed\nMust have minimum age of 21 Years\nMust have maximum age of 90 Years",
    "exclusion_criteria": "In order to participate in this study, a subject Must Not:\n\n* Be younger than 21 years or older than 90 years of age.\n* Have a baseline glomerular filtration rate <35 ml/min 1.73m^2 estimated using the Modification of Diet in renal disease (MDRD) formula.\n* Have an ejection fraction <45% by gated blood pool scan, two-dimensional echocardiogram, cardiac MRI, cardiac CT or left ventriculogram within the past year, as documented by medical history.\n* Have poorly controlled blood glucose levels with hemoglobin A1C > 8.5%.\n* Have a history of proliferative retinopathy or severe neuropathy requiring medical treatment.\n* Have a hematologic abnormality as evidenced by hematocrit < 25%, white blood cell < 2,500/ul or platelet values < 100,000/ul without another explanation.\n* Have liver dysfunction, as evidenced by enzymes (AST and ALT) greater than three times the upper limit of normal.\n* Have a bleeding diathesis or coagulopathy (INR > 1.3), cannot be withdrawn from anticoagulation therapy, or will refuse blood transfusions.\n* Have Lymphadenectomy or Lymph node dissection in the right arm.\n* Be an organ transplant recipient or have a history of organ or cell transplant rejection.\n* Have a clinical history of malignancy within the past 5 years (i.e., subjects with prior malignancy must be disease free for 5 years), except curatively- treated basal cell or squamous cell carcinoma, or cervical carcinoma.\n* Have a condition that limits lifespan to < 1 year.\n* Have a history of drug or alcohol abuse within the past 24 months.\n* Be on chronic therapy with immunosuppressant medication, such as corticosteroids or Tumor Necrosis Factor - alpha (TNFα) antagonists.\n* Be serum positive for HIV, Syphilis - VDRL (Confirmation with FTA-ABS if needed (Syphilis)), hepatitis B surface antigen or viremic hepatitis C.\n* Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.\n* Be pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods.\n* Any other condition that in the judgment of the Investigator would be a contraindication to enrollment or follow-up.",
    "miscellaneous_criteria": ""
}